Brief: Cara Therapeutics receives payments for development of CR845 in Uremic Pruritus

Chong Kun Dang Pharmaceutical

13/10/2015 13:00

Oct 13 (Reuters) - Cara Therapeutics Inc  CARA.O : 
 * Achieves milestone payments from Japan and South Korea partners for 
   development of CR845 in Uremic Pruritus 
 * Says earned a total of $2.5 million in milestone payments under its 
   development and licensing agreements 
 * Agreements with Maruishi Pharmaceutical Company, Ltd. of Japan and Chong Kun 
   Dang (CKD) Pharmaceutical Corp of South Korea 
 
  Source text for Eikon  urn:newsml:reuters.com:*:nGNXVEPDPa 
  Further company coverage  CARA.O  ((Bengaluru Newsroom; +1 646 223 8780))